Portal de investigación
Distribución de la concentración inhibitoria mínima (CIM) de fosfomicina en aislados de Klebsiella pneumoniae y Pseudomonas aeruginosa multirresistentes.
Datos básicos
Objetivos del proyecto
Identificar la distribución de la CIM de fosfomicina en aislamientos de K. pneumoniae y P. aeruginosa resistentes a carbapenémicos portadores de carbapenemasas.
Documentos
- No hay documentos
Participantes
Unidades de investigación
Outputs del proyecto
A Landscaping Assessment and Call-to-Action to Improve Access to Novel Reserve Antibiotics in 14 Low- and Middle-Income Countries
Motta F.; (...); Cohn J.
Article. 10.1002/puh2.70005. 2024
Actualización sobre la resistencia antimicrobiana en instituciones de salud de nivel III y IV en Colombia entre enero del 2018 y diciembre del 2021.
De La Cadena E; (...); Villegas MV
Article. 10.7705/biomedica.7065. 2023
Antimicrobial Stewardship Programs in Latin America and the Caribbean: A Story of Perseverance, Challenges, and Goals
Restrepo-Arbeláez N; (...); Villegas MV
Review. 10.3390/antibiotics12081342. 2023
Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
Pallares CJ; (...); Villegas MV
Article. 10.1186/s12879-023-08398-3. 2023
Burnout as a social pathology in nursing professionals: an analysis based on the theory of recognition;
Article. 10.47626/1679-4435-2022-771. 2022
Can risk factors and risk scores help predict colonization and infection in multidrug-resistant gram-negative bacteria?
RESTREPO, NATALIA; (...); VILLEGAS, MARIA VIRGINIA
Article. 10.1017/ash.2024.455. 2024
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter Baumannii Among Patients From Different Global Regions
Wang, MG; (...); Doi, YH
Article. 10.1093/cid/ciad556. 2023
Consenso de expertos para el tratamiento antimicrobiano de las infecciones causadas por bacilos gram negativos multirresistentes en pacientes adultos
Álvarez-Moreno C.A.; (...); Rojas S.Y.S.
Article. 10.22354/24223794.1130. 2023
First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197
Cadena E.D.L.; (...); VILLEGAS, MARIA VIRGINIA
Article. 10.1128/spectrum.04105-23. 2024
Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed methods needs assessment in France, the United States, Mexico and India (vol 4, pg dlac094, 2022)
Lazure, P; (...); Peloquin, S
Correction. 10.1093/jacamr/dlad010. 2022
Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed-methods needs assessment in France, the United States, Mexico and India - authors' response
Lazure P; (...); Peloquin S
Letter. 10.1093/jacamr/dlad082. 2023
Identification of mcr-1 Genes and Characterization of Resistance Mechanisms to Colistin in Escherichia coli Isolates from Colombian Hospitals
De La Cadena E; (...); Villegas MV
Article. 10.3390/antibiotics12030488. 2023
Latin American consensus on the importance of a microbiological data management system to support antimicrobial use optimization program (PROA): Evidence-based recommendations. Part 1; [Consenso latinoamericano sobre la importancia de un sistema de gestión de datos microbiológicos para apoyar el programa de optimización de uso de antimicrobianos (PROA): Recomendaciones basadas en la evidencia. Parte 1]
PALLARES, CHRISTIAN JOSE; (...); VILLEGAS, MARIA VIRGINIA
Article. 10.4067/s0716-10182024000100036. 2024
Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
Mojica MF; (...); Villegas MV
Article. 10.1128/msphere.00651-22. 2023
Rapid Diagnostic Test Value and Implementation in Antimicrobial Stewardship Across Low-to-Middle and High-Income Countries: A Mixed-Methods Review
Moore LSP; (...); Apisarnthanarak A
Note. 10.1007/s40121-023-00815-z. 2023
Campos de Estudio
Citar el proyecto
Distribución de la concentración inhibitoria mínima (CIM) de fosfomicina en aislados de Klebsiella pneumoniae y Pseudomonas aeruginosa multirresistentes. (UEB-2022-668). 2022-2024. IP:MARIA VIRGINIA VILLEGAS BOTERO.